The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...